… Herein we provide the preclinical and clinical rationale for studies examining the concept
of pharmacodynamic separation as a means for overcoming hypothesized antagonism of …

… with tamoxifen and chemotherapy in breast cancer, or with intermittent dosing of the EGFR
TKI, a concept we have designated as pharmacodynamic separation.The following preclinical …

Background Pharmacodynamic separation of pemetrexed and erlotinib avoids negative
cellular interactions and results in antitumor synergy in erlotinib-resistant non–small-cell lung …

… of rare cells, to isolate cells of interest from lung cancer patients … and pharmacodynamic
analysis of these rare lung cancer cells. … For sample processing the sample was split into two for …

… Samples were centrifuged, and the serum was separated and immediately frozen at -20 C
until the time at which they were assayed. All samples were stored in polypropylene plastic …

… Separation and quantitation of the normal ribonucleotides and of dFdCTP was achieved
with a gradient HPLC (Partisphere SAX anion exchange column, Whatman, Clifton, NJ; length, …

… compared with chemotherapy alone in advanced non-small cell lung cancer (NSCLC).
Pharmacodynamic separation by intermittent delivery of epidermal growth factor receptor tyrosine …

8044 Background: We previously reported that PDS of Pem and Erl (Pem 500 mg/m 2 IV on
day 1 and Erl 150 mg po QD on days 2-17 of a 21-day cycle) as 2 nd -line therapy has …

8097 Background: Preclinical and phase I studies showed that PDS optimizes cytotoxicity of
concurrent EGFR inhibitors and chemotherapy. We conducted a randomized phase II trial to …

… For non–small cell lung cancer (NSCLC), surgery is the only curative option for early-stage
disease. … As in our study, this pharmacodynamic end point did not correlate with clinical tumor …